Third-party supply reports
Posted in News
In the last issue of the newsletter, we showed you a new report that tracked the use of oral chemotherapy drugs helping Trusts ensure the most cost-efficient route of supply.
We have expanded this further with a new suite of reports in Define® and Refine® (Under Third Party Supply ) which will assist Trusts to measure their current third-party drug spend and the potential third-party savings for:
- Oral chemotherapy
- Treatments for HIV
- Hepatitis C
- Multiple sclerosis
Further reports within Refine® will assist Trusts to calculate their NHSE Trigger3 requirements (to increase use of cost-effective dispensing routes for outpatient medicines and implement an agreed transition plan for increasing use of cost-effective dispensing routes for outpatient medicines).